At Baobab Biopharma, every product we manufacture is more than a pill or a vial, it’s a step toward health sovereignty for Africa. By producing essential medicines locally, we reduce reliance on imports, drive down healthcare costs, and create a resilient pharmaceutical future.
This mission fuels every stage of our product development, ensuring that what we make not only saves lives but strengthens Africa’s healthcare independence.
Our Vision: More Than Medicine
Phased Product Roadmap
Phase 1 (Years 1-3): Laying the Foundation -Strategic Launch
Strategic Launch: Building Africa's Pharmaceutical Foundation
Phase 1 focuses on rapidly establishing our WHO prequalified GMP-grade OSD facility in Burkina Faso, launching production of Azithromycin, a key antibiotic addressing critical regional needs. This phase demonstrates our operational excellence and positions us for rapid market entry.
_edited.jpg)
Phase 3 (Years 6+): Innovating for the Future - Diversified Growth
Diversified Growth: Pioneering Advanced Therapies
Phase 3 strategically diversifies our portfolio, introducing biologics, vaccines ((DTP, MMR, Hepatitis B), and targeted small molecules (cardiovascular disease, cancer, and diabetes) to address critical diseases. This phase positions Baobab as a leader in advanced pharmaceutical solutions.
Phase 2 (Years 4-5): Expanding Essential Access - Rapid Scale-Up
Rapid Scale-Up: Meeting Africa's Urgent Needs
Phase 2 expands production to include Artemether-Lumefantrine, Amoxicillin, and Amoxicillin-Clavulanate, broadening our response to Africa's essential medicine needs. Through manufacturing efficiency, regulatory excellence, and supply chain optimization, this phase strengthens our footprint and builds R&D capacity.
Uncompromising Quality:
Global Standards, Local Impact
_edited.jpg)
Our WHO prequalified, cGMP compliant facility ensures every medicine meets rigorous global standards. We combine this with local manufacturing expertise to deliver consistent efficacy and safety, building trust and strengthening Africa's health sovereignty.